Joseph Vento

Joseph Vento: ASCO update on PARPi and ARPI therapy in BRCA-mut mHRPC with Tian Zhang

Joseph Vento, Oncologist at UT Southwestern Medical Center, posted on X:

“Our ASCO update on PARPi+ARPI therapy in BRCA-mut mHRPC

Why diff in combo vs seq crossover in BRCA way? Small n but fascinating results!

Ongoing PARPi combo trials in mHSPC including HARMONY led by Qian Janie Qin.”

Joseph Vento

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) 

Authors: Maha Hussain et al.

Joseph Vento

Arul M. Chinnaiyan cancer Channing J Paller Daniel Shevrin Emmanuel S Antonarakis Jingsong Zhang Joel Picus Latifa A. Bazzi Maha Hussain Masha Kocherginsky Matthew B. Rettig Nabil Adra Neeraj Agarwal OncoDaily Oncology Robert Dreicer Russell Z Szmulewitz Ryan D. Stephenson Scott T. Tagawa Stephanie Daignault-Newton Timothy M. Kuzel Travis Gerke Young E. Whang Zachery R. Reichert